학술논문

Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.
Document Type
Article
Source
Science Translational Medicine; 2/1/2023, Vol. 15 Issue 681, p1-14, 14p
Subject
IMMUNE response
MACULAR degeneration
VASCULAR endothelial growth factors
VASCULITIS
KRA
Language
ISSN
19466234
Abstract
Copyright of Science Translational Medicine is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)